Related to Standardization Key to Taking Next-Generation Sequencing to the Next Level

• Sequencing Study IDs Spontaneous Mutations in Congenital Heart Disease
  
• VC Investment: Not Quite Dead?
  
• Ignyta Snaps Up Actagene, Branches into Cancer Rx/Dx
  
• Dako Inks Cancer Companion Diagnostic Alliance with OSI
  
• Avacta Takes Over TheraGenetics to Expand into Clinical Diagnostics
  
• Clarient Acquires Breast Cancer Biomarker from Indiana University
  
• Minerva Grants Clarient Exclusive Rights to Develop MUC1* Biomarker for Cancer Diagnostics
  
• bioMérieux Teams Up with Knome to Develop Next-Generation Sequencing-Based In Vitro Diagnostics
  
• Helicos Nixes 40 Employees to Focus on Diagnostics
  
• Gen-Probe Invests $50M in PacBio to Fortify Single-Molecule Sequencing Platform
  
• Aeterna Zentaris Taps Almac to Develop Companion Diagnostic for Its Cancer Drug
  
• TcLand Teams Up with Spanish Institute to Develop Assay for Predicting Response to TNFalpha Therapy
  
• OvaGene Licenses Gene-Expression IP for Development of Clinical Cancer Assays
  
• Microfluidics Device that Assesses Her2 Status from Circulating Tumor Cells Developed
  
• Novartis Inks U.S. Commercialization Deal for Cepheid’s Ph+ CML Prognostic Tool
  
• Roche and CapitalBio Partner on Biochip and Next-Gen Sequencing for MDx
  
• AmoyDx Receives SFDA Approval for KRAS Detection Kit
  
• OSEO Pledges €10.4M for Alzheimer Diagnostic, Theranostic, and Therapeutic R&D
  
• Transgenomic Picks Up Clinical Data’s MDx and Biomarker Business for $15.4M
  
• Myriad Takes Over Testing Platform from Melanoma Diagnostics